Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.4K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.4K
Tumor Progression02:07

Tumor Progression

7.9K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.9K
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.5K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE Study.

Cancer research communications·2026
Same author

Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

HLA Class I Expression is Associated with Increased Immune Cell Density and PTEN Loss in Prostate Cancer.

Molecular cancer research : MCR·2026
Same author

Evaluation of Tissue from Patients with Prostate Cancer Identifies B7-H3 as an Androgen-Regulated, Broadly-Expressed, Combinatorial Therapeutic Target.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Treatment-Free Survival: A Novel Endpoint in Trials of Stereotactic Body Radiation With or Without Systemic Therapy.

International journal of radiation oncology, biology, physics·2026
Same author

The molecular pathology of prostate cancer: an update for practising pathologists.

Histopathology·2026
Same journal

Letter to the Editor Regarding "Microbial Differences in Prostate Lesions Between Black and White American Men".

The Prostate·2026
Same journal

Years of Life Lost From Metastatic Prostate Cancer According to Treatment Era and Race/Ethnicity.

The Prostate·2026
Same journal

Hematological Inflammation Markers in the Prediction of Clinically Significant Prostate Cancer and the Individualization of Biopsy Decisions for PI-RADS 3 Lesions: A Two-Center Retrospective Study.

The Prostate·2026
Same journal

Enhancing Continence Recovery After Robot-Assisted Radical Prostatectomy: A Novel Combined Approach Using Testosterone Therapy and Magnetic Stimulation.

The Prostate·2026
Same journal

Comprehensive Characterization of Metastatic Patterns and a Redefined Prognostic Framework in Metastatic Prostate Cancer.

The Prostate·2026
Same journal

Real-World Clinical Evaluation of S2,3PSA Test in a Prostate Biopsy Cohort With PSA Level of 4-10 ng/mL.

The Prostate·2026
See all related articles

Related Experiment Video

Updated: Apr 10, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Castration Resistance Accelerates Prostate Cancer Kinetics.

Sheila Jonnatan1, Luka Cavka1, Angelo M De Marzo1

  • 1Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.

The Prostate
|April 8, 2026
PubMed
Summary
This summary is machine-generated.

Prostate cancer progresses faster when it becomes castration-resistant. This accelerated growth, measured by prostate-specific antigen doubling time (PSADT), may impact survival for patients with indolent disease.

Keywords:
Prostate cancercancer kineticscastration resistanceprostate‐specific antigen doubling time

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

48.2K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.2K

Related Experiment Videos

Last Updated: Apr 10, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

48.2K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.2K

Area of Science:

  • Oncology
  • Urology
  • Cancer Research

Background:

  • Prostate cancer is often indolent, allowing long survival.
  • Castration therapy has been used for over 70 years.
  • The impact of castration resistance on prostate cancer progression rate is not well understood.

Purpose of the Study:

  • To quantify the change in prostate-specific antigen doubling time (PSADT) before and after castration resistance develops.
  • To investigate the relationship between PSADT and overall survival in castration-resistant prostate cancer (CRPC).

Main Methods:

  • Longitudinal analysis of PSADT in 40 prostate cancer patients before and after castration resistance.
  • Correlation analysis of CR-PSADT with overall survival and Ki-67 index in a separate cohort of 36 metastatic CRPC patients.

Main Results:

  • Castration-resistant prostate cancer (CR-PSADT) showed a significantly shorter median PSADT (2.6 months) compared to castration-naïve prostate cancer (CN-PSADT) (5.8 months).
  • CR-PSADT positively correlated with CN-PSADT and overall survival.
  • A negative correlation was found between CR-PSADT and the Ki-67 proliferation index in metastatic tumor biopsies.

Conclusions:

  • Castration resistance markedly accelerates prostate cancer kinetics.
  • This accelerated progression may negatively impact survival, particularly if androgen deprivation therapy (ADT) is initiated prematurely in indolent cases.